Ryan Cross

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

Spot­light Ther­a­peu­tics, a start­up with a bold vi­sion for de­liv­er­ing CRISPR ther­a­pies in­to the body with­out the need for vi­ral vec­tors or lipid nanopar­ti­cles, has

The hu­man genome is chock-full of mid­dle man­agers. Rough­ly 2,000 pro­teins, ac­count­ing for one-tenth of our genes, con­trol how the rest … Sign up to

Alzheimer’s dis­ease has af­flict­ed Han­nah Richard­son’s fam­i­ly for gen­er­a­tions. A rare ge­net­ic mu­ta­tion, passed down from her great-grand­moth­er, has struck her rel­a­tives with the first

Fer­til­i­ty start­up Ga­me­to has re­ceived per­mis­sion from the FDA to see if its ovary-in-a-dish tech­nol­o­gy can make in vit­ro fer­til­iza­tion a less gru­el­ing process, the

In­tel­lia Ther­a­peu­tics is the lat­est CRISPR com­pa­ny re­sort­ing to lay­offs as in­vestors in­creas­ing­ly turn away from gene edit­ing.The Cam­bridge, MA-based com­pa­ny an­nounced Thurs­day that …